From Collapse to Comeback: Is This the Next Biotech Breakout?
Once a pandemic-era superstar, this biotech stock has plummeted over 85% — but beneath the surface, something is shifting. With insider buying, a strong cash position, and a promising pipeline in cancer and respiratory treatments, it may be on the verge of a powerful rebound. While most investors look away, the real opportunity is taking shape right now.
Don’t wait for Wall Street to catch up.
Get ahead of the crowd and access our full analysis






